Register Login

Bleeding Disorders

Sep 17 2025
george

A Review of Current and Developing DOAC Reversal Agents

Check with your medical library for this comprehensive review of current and developing DOAC reversal agents:  Gómez-Outes A, Suárez-Gea ML, Lecumberri R. When and how to use reversal agents for direct oral anticoagulants? Curr Cardiol Rep. 2023;25:371–80. doi: 10.1007/s11886-023-01858-x. PMID: 36976497. Abstract Purpose of review: Our objective is to describe currently available reversal agents for […]
read more
Comments (0)
Anticoagulant Therapy
Sep 10 2025
george

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

To review the PBI poster presented at the 2025 ISTH meeting, click Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel, Bovine Chromogenic FVIII Assay. Tara Quinton, Meghan Bruhm, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada. The poster illustrates the validity of bovine reagent-based chromogenic substrate FVIII […]
read more
Comments (0)
Bleeding Disorders
Aug 30 2025
george

NXT007: A First-in-human Study of a Factor Bypassing Hemophilia Therapy

Check with your medical library for a copy of  Sambe T, Miwa T, Yoneyama K, et al. A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants. J Thromb Haemost. 2025: S1538–7836(25)00399-X. doi: 10.1016/j.jtha.2025.06.013. PMID: 40554054. Here’s the abstract: Background: NXT007 is a bispecific antibody that mimics the cofactor function […]
read more
Comments (0)
Bleeding Disorders
Jul 29 2025
george

July 2025 QQ: Hemophilia Rebalancing Therapy

Our July 2025 Quick Question asked, “Which is a hemophilia ‘rebalancing’ therapeutic?” The question attracted a modest 22 participants, perhaps an indication that rebalancing therapy was only FDA-approved in 2025 and awaits approval in Canada and Europe. Here are your responses… Valoctocogene roxaparvovec-rvox (ROCTAVIAN) 3 (14%) Efanesoctocog alfa (ALTUVIIIO) 1 (4%) Emicizumab (HemLibra) 7 (32%) […]
read more
Comments (0)
Quick Question Archive
Jul 22 2025
george

Autoimmune Acquired Coagulation Factor Deficiencies

Click here for the open-access review of Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost. 2025;51:491-505. doi: 10.1055/s-0044-1787188. Epub 2024 Jun 12. PMID: 38866039. Abstract Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and […]
read more
Comments (0)
Bleeding Disorders
Jul 22 2025
george

Postpartum DIC

Check with your medical library for this review, dated 7-18-25. Wolfovitz A, Brenner B, Solt I. Postpartum disseminated intravascular coagulation: A comprehensive review of pathophysiology, diagnosis, management, and prevention. Semin Thromb Hemost. doi: 10.1055/a-2645-2845. Epub ahead of print. PMID: 40680793. Abstract Disseminated intravascular coagulation (DIC) in the postpartum period is a rare but potentially life-threatening […]
read more
Comments (0)
Fibrinolysis
Load more

George Fritsma MS MLS

George Fritsma is a medical laboratory scientist, educator, and author. George  is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

Cheat Sheets from George

Name

Questions or Comments?

Email George

Quick Question

Which is NOT an antiphospholipid antibody?